Stereotaxis, Inc.

4320 Forest Park Avenue
Suite 100
St. Louis
Missouri
63108
United States

Tel: 314-678-6100
Fax: 314-678-6300

Show jobs for this employer

245 articles with Stereotaxis, Inc.

  • Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medical Center is establishing a robotic electrophysiology program to expand access to advanced minimally-invasive treatment of heart rhythm disorders in Florida.

  • Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced it will move its global headquarters to the Globe Building in downtown St. Louis at the end of this year.

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro environment,” said David Fischel, Chairman and CEO.

  • Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced a 10-year CEO performance stock award for David Fischel with vesting entirely contingent upon the company achieving billion-dollar market capitalization milestones.

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in the first quarter 2021.

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 third quarter on Monday, November 9, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments. What: Stereotaxis

  • Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced it has completed installations of the world’s first Genesis Robotic Magnetic Navigation systems to treat heart rhythm disorders at Helsinki University Hospital in Finland and Banner - University Medicine Heart Institute in Phoenix, Arizona.

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will serve as a panel speaker at the plenary session of RAPS Convergence 2020 . RAPS Convergence is the largest annual gathering of regulatory professionals in healthcare and is hosted by the Regulatory Affairs Professionals Society. The plenary session will take place on

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2020. “Stereotaxis responded to the challenges of COVID-19 with resilience, prudence and creativity. Despite a 21% year-over-year reduction in quarterly revenue caused by procedure declines, we have made significant progress in commercializing the Genesis

  • Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting from remote TeleRobotic Support. Dr. Gery Tomassoni of Baptist Health in Lexington, KY treated the patient utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems supported by technical and clinical experts from each company using proprietary connectivity technology. The

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the European Heart Journal highlighting the benefits of Stereotaxis’ robotic technology in a COVID-19 patient. The publication concludes that catheter ablation “should be performed preferably with a remote navigation system in order to minimize the infectious risk of the staff of the electrop

  • Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that the company will be added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. stock market closes on Friday, June 26, 2020, as part of the Russell Indexes annual reconstitution.

  • Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that David Fischel, Chairman and CEO, will present at the Cowen 5th Annual FutureHealth Conference on Thursday, June 25, 2020 at 10:15 am EDT.

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain funds managed by Consonance Capital Management, a prominent healthcare-focused institutional investor. Stereotaxis is issuing approximately 3.66 million shares of registered common stock at a purchase price of $4.10 per share, for gross and net pr

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2020. “Despite the challenges and disruptions inflicted by COVID-19, Stereotaxis continues to support the patients and physicians that rely on its technology, maintain effective operations, rapidly advance strategic innovations, and protect its financial s

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 first quarter on Tuesday, May 5, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments. What:   Stereotax

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019.

  • Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Genesis RMN® System for the robotic navigation of magnetic ablation catheters to treat heart rhythm disorders.

  • Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that David Fischel, Chairman and CEO, will present at three investor conferences in March 2020.

  • A video of the bell-ringing will also be archived on that same page following the livestream.